UGT1A1 GENE POLYMORPHISM

UGT1A1 Gene Polymorphism is a specialized molecular genetic test used to identify variations in the UGT1A1 gene, which plays an important role in the metabolism and elimination of bilirubin and certain medications. Genetic changes in the UGT1A1 gene can affect enzyme activity, leading to altered bilirubin processing and variations in drug metabolism.

This test is commonly performed to evaluate inherited conditions such as Gilbert syndrome, investigate unexplained elevated bilirubin levels, and assess the risk of adverse reactions to specific medications including irinotecan. Identification of UGT1A1 polymorphisms helps physicians personalize treatment plans and improve medication safety.

Benefits of the Test

• Detects clinically significant UGT1A1 genetic variants.
• Supports diagnosis of Gilbert syndrome.
• Helps evaluate unexplained elevated bilirubin levels.
• Assists in personalized medication selection.
• Identifies risk of irinotecan-related toxicity.
• Supports pharmacogenomic treatment planning.
• Provides valuable hereditary genetic information.
• Helps improve patient safety and treatment outcomes.

Why Doctors Recommend This Test

Doctors recommend UGT1A1 Gene Polymorphism testing for patients with persistent unconjugated hyperbilirubinemia, suspected Gilbert syndrome, unexplained jaundice, or before initiating medications such as irinotecan that may be affected by UGT1A1 enzyme activity. The test helps guide diagnosis, treatment decisions, and medication dosing strategies.

Preparation Before Test

• No fasting is generally required.
• A blood sample is collected for genetic analysis.
• Provide relevant medical and family history.
• Inform your doctor about current medications.
• Share previous laboratory and genetic test reports if available.
• Follow all sample collection instructions provided by the laboratory.

Normal Reporting Time

Most UGT1A1 Gene Polymorphism reports at Focus Diagnostics are initiated within 2–3 hours of sample receipt for accessioning, DNA extraction, and molecular workflow preparation. Final genetic analysis, variant interpretation, quality review, and report generation are generally completed within several working days depending on laboratory protocols and quality assurance requirements.

Who Should Take This Test?

This test may be recommended for:

• Patients with suspected Gilbert syndrome.
• Individuals with unexplained elevated bilirubin levels.
• Patients with recurrent mild jaundice.
• Individuals undergoing irinotecan therapy.
• Patients requiring pharmacogenomic evaluation.
• People with a family history of UGT1A1-related disorders.
• Individuals with abnormal liver function investigations.
• Patients seeking personalized medicine guidance.

Detailed Information

The UGT1A1 gene encodes the enzyme uridine diphosphate glucuronosyltransferase 1A1, which is responsible for converting bilirubin into a form that can be eliminated from the body. Reduced enzyme activity due to genetic polymorphisms can lead to elevated levels of unconjugated bilirubin and mild jaundice.

One of the most common conditions associated with UGT1A1 polymorphisms is Gilbert syndrome, a benign inherited disorder characterized by intermittent increases in bilirubin levels. Although Gilbert syndrome is generally harmless, accurate diagnosis can prevent unnecessary investigations and provide reassurance to patients.

UGT1A1 genetic testing is also an important component of pharmacogenomics. Certain medications, particularly irinotecan used in cancer treatment, are metabolized through pathways involving UGT1A1. Individuals with specific UGT1A1 variants may be at increased risk of severe medication toxicity, including neutropenia and gastrointestinal side effects.

The test uses advanced molecular biology techniques to identify clinically relevant genetic variants within the UGT1A1 gene. Results are interpreted by molecular genetics specialists and correlated with clinical findings, laboratory data, and treatment history.

Identification of UGT1A1 polymorphisms can help physicians optimize medication dosing, reduce adverse drug reactions, support genetic counseling, and improve individualized patient care. The information obtained from this test may be valuable throughout a patient's lifetime because genetic variations remain unchanged.

Results should always be interpreted in conjunction with clinical assessment and physician recommendations. Additional laboratory or genetic investigations may be advised depending on the patient's symptoms and medical history.

At Focus Diagnostics, UGT1A1 Gene Polymorphism testing is performed using advanced molecular diagnostic technologies, validated genetic analysis methods, and stringent quality assurance standards to provide accurate, reliable, and clinically meaningful genetic testing results.